Shipra Gandhi, MD, MS

One star
One star
One star
One star
One half star

Rating: 4.8 out of 5 (45 ratings)

Role

Breast Medical Oncology
Specialty

Breast Cancer
Research Program

Cancer Immunology
Practicing Since

2018

Background

A board-certified medical oncologist, Shipra Gandhi, MD, MS, treats patients with breast cancer at Winship Cancer Institute's Clifton campus. As a physician-scientist, her research interest is in studying immunosuppression in the tumor microenvironment and developing strategies to overcome it in triple-negative breast cancer, an aggressive type of breast cancer.

Dr. Gandhi is an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Before joining Emory, she was on faculty and an attending physician at Roswell Park Comprehensive Cancer Center in Buffalo, New York.

Dr. Gandhi received her medical degree from Lady Hardinge Medical College in New Delhi, India. She completed her internal medicine residency at The State University of New York (SUNY), followed by her fellowship in hematology and oncology at Roswell Park Comprehensive Cancer Center in Buffalo, New York. She also earned a Master of Science from The State University of New York (SUNY)

Titles & Roles

Associate Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine
Director of Breast Translational Research, Glenn Family Breast Center

Winship Cancer Institute of Emory University
Co-Chair, Data and Safety Monitoring Committee

Winship Cancer Institute of Emory University

Education & Training

Education

Professional Education, MS, Epidemiology, 2024
SUNY - Buffalo, School of Med & Biomedical Studies
Fellowship, Hematology/Oncology, 2018
Roswell Park Cancer Institute
Residency, Internal Medicine, 2015
SUNY - Buffalo, School of Med & Biomedical Studies
Internship, 2010
Lady Hardinge Medical College & Associated Hospitals
Medical Education, MD, 2010
University of New Delhi

Board Certifications

Medical Oncology
American Board of Internal Medicine, 2018
Hematology
American Board of Internal Medicine, 2018
Internal Medicine
American Board of Internal Medicine, 2015

Professional Memberships

American Society of Clinical Oncology
American College of Physicians
Society for Immunotherapy of Cancer

Research

Dr. Gandhi's research focuses on immunosuppression in the tumor microenvironment and on developing strategies to overcome it in triple-negative breast cancer, an aggressive and deadly subtype.

View Current Clinical Trials


SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers Phase II Conditions Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-low Breast Cancer Location Emory University Hospital Midtown, Emory Saint Joseph's Hospital, Winship Cancer Institute
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma Phase I Conditions Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma, Gastrointestinal Cancer, Lung Cancer, Prostate Cancer, Breast Cancer Location Emory University Hospital Midtown, Winship Cancer Institute
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Phase II Conditions Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer Location Emory University Hospital Midtown, Emory Saint Joseph's Hospital, Winship Cancer Institute
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors Phase I/II Conditions Advanced Solid Tumor Location Winship Cancer Institute
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab Phase III Conditions Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2+ Breast Cancer Location Emory University Hospital Midtown, Emory Saint Joseph's Hospital, Emory Johns Creek Hospital, Emory Decatur Hospital, Winship Cancer Institute
Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer Phase II Conditions Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Refractory Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma Location Emory Saint Joseph's Hospital, Emory Johns Creek Hospital, Emory Decatur Hospital, Winship Cancer Institute
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer Phase I Conditions Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer Location Winship Cancer Institute
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer Phase I/II Conditions Breast Cancer Location Emory University Hospital Midtown, Winship Cancer Institute

Grants

View Grants

Grant Number	Title
5K08CA279766-03	Stress-induced immunosuppression via downregulation of interferon in triple negative breast cancer
5K08CA279766-04	Stress-induced immunosuppression via downregulation of interferon in triple negative breast cancer
7K08CA279766-02	Stress-induced immunosuppression via downregulation of interferon in triple negative breast cancer

Publications

Title/Journal	Authors	Publication Date
Emerging Strategies Targeting the PI3K/AKT/mTOR Pathway in HR+/HER2- Advanced Breast Cancer. Drugs	L Lei, M Canning, E Sakach, A Lateef, L Kamga, M Abid, K Kalinsky, S Gandhi	07/28/2026
A Neuron Projection Guidance Signature Associates with Immune-Cold Tumor Microenvironment and Poor Outcomes in Breast Cancer. Annals of surgical oncology	K Kawashima, K Chida, M Oshi, A Yamada, K Narui, S Gandhi, JML Ebos, SI Abrams, A Bhattacharjee, I Endo, K Takabe	07/25/2026
Racial and ethnic disparities in clinical outcomes of HER2-positive metastatic breast cancer treated with antibody-drug conjugates. Journal of the National Cancer Institute	Z Shah, L Lei, R Thakur, A Buradkar, M Alharbi, M Ombada, S Yao, A Chua, H Yu, S Badve, T Khoury, A Madabhushi, U Baid, K Kalinsky, S Kabraji, S Gandhi	07/07/2026
ASO Author Reflections: Neuronal Signature Enrichment Distinguishes a Type of Gastric Cancer with Poor Prognosis. Annals of surgical oncology	M Oshi, S Gandhi, K Takabe	05/28/2026
TP53 mutation is associated with shorter treatment duration with CDK4/6 inhibitors, but not with immune checkpoint inhibitors, in ER-positive/HER2-negative breast cancer: real-world perspective. Breast cancer research : BCR	M Oshi, M Sugimori, K Kawashima, S Gandhi, A Yamada, K Narui, T Ishikawa, I Endo, K Takabe	05/22/2026
MuTriM: A multiscale deep learning model integrating longitudinal radiomics and pathomic features for predicting recurrence and adjuvant radiation benefit in breast cancer. European journal of cancer (Oxford, England : 1990)	X Wang, L Chen, J Sun, S Khalighi, T Dam, H Maurya, T Pathak, C Lu, S Gandhi, S Badve, S Zhao, W Yang, J Xu, A Madabhushi, B Song	05/02/2026
Is more always better? Low-dose pembrolizumab as a practical step toward more equitable triple-negative breast cancer care. Annals of oncology : official journal of the European Society for Medical Oncology	R Sacks, S Gandhi	05/01/2026
Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B41 Clinical Trial Validation. Clinical cancer research : an official journal of the American Association for Cancer Research	S Bharadwaj, G Corredor, H Al-Shakhshir, S Medina, SN Almahfouz, R Dhamdhere, T Pathak, P Fu, Y Liu, S Gandhi, S Badve, A Madabhushi	03/31/2026
BIO26-046: Validating an LLM for Detecting Enrollment Disparities in Breast Cancer Trials. Journal of the National Comprehensive Cancer Network : JNCCN	Z Shah, S Aziz, M Haji, F Aslam, A Buradkar, U Baid, S Gandhi, S Kabraji	03/31/2026
Neurotoxicity of Immunotherapy: Immune Checkpoint Inhibitor-Related Encephalitis vs. Immune Effector Cell-Associated Neurotoxicity Syndrome. World journal of oncology	T Sato, K Chida, S Gandhi, K Takabe	02/01/2026
Caution over haste: why novel endocrine therapy in early lines should wait in Estrogen receptor positive human epidermal growth factor receptor 2 negative breast cancer. Breast cancer research : BCR	L Lei, M Bhave, K Kalinsky, S Gandhi	01/22/2026
Area deprivation index and breast cancer outcomes among patients in Western New York. Breast cancer research and treatment	M Alharbi, J Krishnan, AM Roy, A Patel, A Kapoor, R Patel, K Catalfamo, K Attwood, H Yu, V Gupta, S Kabraji, K Takabe, T Khoury, E Levine, A Omilian, E Bouchard, S Yao, S Gandhi	08/01/2025
Breast biomarkers evolution between primary and distant metastasis: incidence and significance. Histopathology	M Khedr, S Gandhi, AM Roy, M Alharbi, A George, K Attwood, T Khoury	04/01/2025
HSR25-170: Investigating Socioeconomic and Racial Disparities in Pathologic Response and Survival Outcomes in Triple-Negative Breast Cancer Post-Neoadjuvant Chemotherapy: Insights From the National Cancer Database. Journal of the National Comprehensive Cancer Network : JNCCN	Z Shah, M Alharbi, M Fang, H Yu, S Gandhi	03/28/2025

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.

4.9	One star One star One star One star One half star	Provider showed concern
4.8	One star One star One star One star One half star	Provider explained things clearly
4.7	One star One star One star One star One half star	Provider discussed treatment options
4.8	One star One star One star One star One half star	Provider included you in decisions
4.8	One star One star One star One star One half star	Likelihood of recommending this provider

View Reviews


One star One star One star One star One star	11/15/2025	Good
One star One star One star One star One star	09/10/2025	I like Dr. Gandhi's calm manner. She is very willing to explain things where I can understand them.
One star One star One star One star One star	07/01/2025	Very professional and nice staff.